Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today ...

Opko Health ( ($OPK) ) just unveiled an update. On September 15, 2025, OPKO Health, Inc. completed the sale of certain assets ...

Labcorp has completed its previously announced acquisition of select assets of BioReference Health, a wholly owned subsidiary ...

Dr. Brian Caveney discusses how Test Finder, a novel generative AI tool, can ease clinicians’ EHR burdens through enhanced ...

Access to rapidly developing diagnostic technology such as blood-based biomarkers for early detection and subsequent ...

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a ...

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...